Humanized anti-H7N9 avian influenza virus high-affinity antibody 10K and application thereof

Abstract

The invention discloses a humanized anti-H7N9 avian influenza virus high-affinity antibody 10K filtered and obtained based on a single cell separation technology, the amino acid sequences of light chain and heavy chain variable regions of the antibody are shown as SEQ ID No. 2 and SEQ ID No. 5 respectively. The high-affinity specificity of the antibody is combined with H7N9 avian influenza virus 7 type hemagglutinin protein, and can mediate the kill and wound (ADCC) of effector cells using NK cells as main parts for H7N9 influenza virus infected cells. The antibody 10K can be used for therapeutic development of highly pathogenic avian influenza infection, and also can be used for development of H7N9 influenza virus antigen dectection reagents.

Description

technical field

[0001] The invention relates to the fields of genetic engineering, single cell sorting technology and antibody library display technology, in particular to a human-sourced anti-H7N9 avian influenza virus high-affinity antibody 10K and its application. Background technique

[0002] Since February 2013, cases of human infection caused by H7N9 avian influenza virus have been found in southeast China, gradually spreading from Shanghai and Anhui to other provinces and cities across the country. As of February 2017, a total of 1079 cases of H7N9 influenza infection have been reported nationwide, with 417 deaths and a death rate as high as 38.6%. At present, there is no specific drug for the treatment of highly pathogenic avian influenza infection, and the curative effect of the existing non-specific neuraminidase inhibitor-oseltamivir is limited to the early stage of infection. Since the early symptoms of highly pathogenic H7N9 infection are not significantly diff...

Images